AN OPEN-LABEL EXTENSION (OLE), LONG-TERM SAFETY AND TOLERABILITY STUDY OF PLECANATIDE IN PATIENTS WITH CHRONIC IDIOPATHIC CONSTIPATION (CIC)

Registry ID

SP304203-01

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

SYNERGY PHARMACEUTICALS INC

Start date

2014-09-29

Last update

2014-03-07

Conditions

• IDIOPATHIC CONSTIPATION

Related clinical trials

• A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL IN PATIENTS WITH CHRONIC IDIOPATHIC CONSTIPATION TO DEMONSTRATE THE EFFICACY AND SAFETY OF ELOBIXIBAT 5 MG AND 10 MG FOR 26 WEEKS.
• A MULTICENTER, OPEN-LABEL, SAFETY AND TOLERABILITY EXTENSION TRIAL OF 5 MG AND 10 MG ELOBIXIBAT DAILY IN THE TREATMENT OF CHRONIC IDIOPATHIC CONSTIPATION.

View on source registry